HCPLive
Described by the AAN as “the world's most important annual event for neurologists and neuroscience professionals,” the 2013 annual meeting will offer cutting-edge scientific presentations and comprehensive educational programs to more than 10,000 attendees from across the globe.
American Academy of Neurology 2013 Annual Meeting

American Academy of Neurology 2013 Annual Meeting | AAN 2013

Conference Coverages

Novel Cerebrospinal Fluid Biomarkers Can Be Used to Distinguish Underlying Pathology in Patients with Specific Form of Dementia
Novel Cerebrospinal Fluid Biomarkers Can Be Used to Distinguish Underlying Pathology in Patients with Specific Form of Dementia
Ability to differentiate between subtypes of frontotemporal lobar degeneration could accelerate research into the pathology and prevention of this disease and aid in the design of disease-modifying therapies.
Glutathione Levels Decreased in the Motor Cortex of Patients with Amyotrophic Lateral Sclerosis
Study results suggest that oxidative stress may play a direct role in the neurodegeneration that occurs in ALS.
Assessing Changes in Dementia Diagnostic Category in Patients with Dementia with Lewy Bodies
DaTscan™ SPECT imaging can help physicians assess diagnostic category and improve diagnostic confidence for patients with dementia with Lewy bodies.
Looking for Effective Treatment Options for Painful Diabetic Peripheral Neuropathy
Severe neuropathic pain due to diabetic peripheral neuropathy is associated with negative health impact and increased healthcare utilization, underscoring the need for the development of safe and effective treatments.
Pharmacologic Treatment Options for Partial Seizures
Study results show a novel formulation of oxcarbazepine may provide long-term seizure reduction in patients with refractory epilepsy, while a separate trial produced promising results for long-term lacosamide treatment in elderly patients with partial-onset seizures.
MAP0004 for the Treatment of Severe Pain Associated with Migraine
Data presented at the 2013 AAN Annual Meeting indicate that MAP0004, which delivers dihydroergotamine (DHE) via oral inhalation, is effective in the acute treatment of severe migraine pain.
Droxidopa Shows Promise as a Treatment for Neurogenic Orthostatic Hypotension Symptoms in Patients with Parkinson's Disease
Patients with Parkinson’s disease and neurogenic orthostatic hypotension treated with droxidopa showed improvements in symptoms of dizziness and lightheadedness, and in systolic blood pressure.

Most Popular

$vacMongoViewPlus$ $vAR$